Analysts Set Hims & Hers Health, Inc. (NYSE:HIMS) Price Target at $31.43

Hims & Hers Health, Inc. (NYSE:HIMS) has been assigned an average rating of “Hold” from the sixteen brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, eleven have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $31.4333.

A number of analysts have recently weighed in on HIMS shares. Barclays increased their price objective on Hims & Hers Health from $29.00 to $39.00 and gave the company an “overweight” rating in a research note on Wednesday, June 17th. Weiss Ratings lowered shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a report on Tuesday, May 12th. Citigroup increased their price target on shares of Hims & Hers Health from $28.00 to $35.00 and gave the company a “neutral” rating in a research report on Thursday, July 23rd. BTIG Research reissued a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Finally, Bank of America boosted their price objective on shares of Hims & Hers Health from $36.00 to $37.00 and gave the company a “neutral” rating in a research report on Thursday, July 9th.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Revenue reached approximately $753.2 million, up 38.2% year over year and ahead of the roughly $698.9 million analyst consensus. The company cited strong subscriber growth and broader personalized healthcare offerings as key drivers. Hims & Hers raises annual forecast revenue on strong subscriber growth
• Positive Sentiment: Hims & Hers raised its 2026 revenue forecast to $3.1 billion-$3.3 billion from $2.8 billion-$3.0 billion, above the approximately $3.0 billion consensus. It also issued third-quarter revenue guidance of $880 million-$900 million, above expectations of $845.9 million. Hims & Hers Health Boosts Revenue Target, Swings to Second-Quarter Loss
• Neutral Sentiment: The company said nearly 3 million people rely on its platform, reinforcing the importance of subscriber growth to its long-term expansion strategy. Hims & Hers Health Reports Second Quarter 2026 Financial Results
• Negative Sentiment: Hims & Hers reported a quarterly loss instead of the expected smaller loss, compared with a profit in the prior-year quarter. The earnings miss highlighted continued pressure on margins and profitability despite rapid sales growth. Hims & Hers Reports Q2 Loss, Tops Revenue Estimates
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations or fiduciary-duty breaches. These announcements do not establish wrongdoing but add legal and headline risk for shareholders. Kaplan Fox Investigation Announcement

Hims & Hers Health Trading Up 0.7%

Shares of HIMS stock opened at $31.81 on Friday. The stock has a market capitalization of $7.36 billion, a PE ratio of -353.44, a P/E/G ratio of 88.90 and a beta of 2.40. Hims & Hers Health has a 1-year low of $13.74 and a 1-year high of $65.30. The business has a 50-day moving average of $31.94 and a 200 day moving average of $26.07. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. During the same period last year, the firm earned $0.20 earnings per share. Hims & Hers Health’s revenue for the quarter was up 3.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Hims & Hers Health will post 0.03 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Patrick Harrison Carroll sold 23,726 shares of the firm’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $35.00, for a total value of $830,410.00. Following the sale, the insider directly owned 181,861 shares of the company’s stock, valued at $6,365,135. This trade represents a 11.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 7,163 shares of the business’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $36.49, for a total value of $261,377.87. Following the transaction, the chief financial officer owned 284,321 shares in the company, valued at approximately $10,374,873.29. This represents a 2.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 83,126 shares of company stock valued at $2,711,339 over the last ninety days. Corporate insiders own 11.76% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds have recently made changes to their positions in the business. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after acquiring an additional 319 shares in the last quarter. Sigma Planning Corp boosted its stake in Hims & Hers Health by 1.5% during the 1st quarter. Sigma Planning Corp now owns 26,007 shares of the company’s stock valued at $540,000 after purchasing an additional 388 shares during the last quarter. Captrust Financial Advisors boosted its position in shares of Hims & Hers Health by 3.1% during the second quarter. Captrust Financial Advisors now owns 14,612 shares of the company’s stock valued at $728,000 after buying an additional 443 shares during the last quarter. Binnacle Investments Inc purchased a new stake in shares of Hims & Hers Health during the 3rd quarter valued at about $28,000. Finally, Cura Wealth Advisors LLC grew its position in Hims & Hers Health by 8.5% in the 4th quarter. Cura Wealth Advisors LLC now owns 6,512 shares of the company’s stock worth $211,000 after purchasing an additional 512 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.